Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Somogyi hypothesis: a parallelism with Michael Somogyi's life.
Hormones (Athens)
December 2024
Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias/University of Oviedo, Oviedo, Spain.
Michael Somogyi (Somogyi Mihály, 1883-1971) was a Hungarian biochemist who developed his scientific career in Europe and, primarily, the United States. He gave the name to the eponymous Somogyi effect or Somogyi hypothesis (in short, rebound hyperglycemia after insulin-induced hypoglycemia, particularly nocturnal), which was an axiom in the treatment of diabetes for decades. Although it is currently debated whether the Somogyi hypothesis is a real or relevant phenomenon in patients with diabetes, Somogyi's other significant career achievements are often overlooked.
View Article and Find Full Text PDFProbing the contact time of droplet impacts: From the Hertz collision to oscillation regimes.
Phys Rev E
November 2024
Department of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.
Droplet rebound on nonwetting surfaces is a common phenomenon. However, the underlying physics regulating the contact time remains unclear. In this work, we investigate droplet impacts on superamphiphobic surfaces through experiments and theoretical analyses.
View Article and Find Full Text PDFSevere Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review.
Neuropediatrics
December 2024
Department of Pediatric Neurology, Jena University Hospital, Jena, Germany.
Adult reports of unexpected severe disease worsening, often termed "rebound," shortly after discontinuing fingolimod in a subset of patients with multiple sclerosis (MS), have grown over the last decade. This phenomenon, however, remains poorly described in pediatric MS patients. We present findings of a 15-year-old who experienced a debilitating relapse 4 weeks after stopping fingolimod to switch to ocrelizumab.
View Article and Find Full Text PDFOur Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation.
Adv Ther
November 2024
Department of Dermatology, Rambam Health Care Campus, 8th Ha'aliya Hashnia, 3109601, Haifa, Israel.
Article Synopsis
- - Infantile hemangioma (IH) is a common benign tumor in infants that typically resolves on its own, but some cases require treatment with propranolol, which has a high success rate but may lead to rebound growth when stopped.
- - A study of 552 patients found that 12.6% experienced rebound growth after discontinuing propranolol; limb involvement predicted a lower likelihood of rebound growth, while younger age and a specific dose of 2 mg/kg/day improved treatment responses.
- - The research concluded that IHs on limbs displayed reduced rebound growth and better responses to propranolol, highlighting the importance of early treatment initiation and appropriate dosing for better outcomes.
Objective: To investigate a dose-response relationship between the magnitude of decrease in pediatric respiratory tract infections (RTI) during the 2020 implementation of non-pharmaceutical interventions (NPI) and the rise thereafter during NPI lifting.
Study Design: We conducted an interrupted, time-series analysis, based on a multinational surveillance system. All patients <16 years of age coming to medical attention with various symptoms and signs of RTI at 25 pediatric emergency departments from 13 European countries between January 2018 and June 2022 were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!